Alnylam Pharmaceuticals Profit Margin 2006-2021 | ALNY
Current and historical gross margin, operating margin and net profit margin for Alnylam Pharmaceuticals (ALNY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Alnylam Pharmaceuticals net profit margin as of June 30, 2021 is -128.96%.
|Alnylam Pharmaceuticals Annual Profit Margins
|Alnylam Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.